ghk cu copper peptide injection GHK-CU The Effect of the Human

The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons

:

National Institute of Diabetes and Digestive and Kidney Diseases

The effect typically diminishes after the first few days as the body adjusts

Frequency varies by peptide: BPC-157 is typically dosed twice daily